Abstract
Albertsons Companies, Inc. is scheduled to release quarterly results on July 23, 2026 Pre-MKt, and consensus indicators point to modest year-over-year revenue growth and slightly higher adjusted EPS; this preview summarizes the key expectations, prior-quarter performance, segment trends, and prevailing analyst sentiment.Market Forecast
Based on current-quarter forecasts, Albertsons Companies, Inc. is expected to generate approximately 24.82 billion US dollars in revenue, implying 0.36% year-over-year growth, with adjusted EPS projected at around 0.55 and a 2.70% year-over-year increase; EBIT is expected at about 480.81 million US dollars with a year-over-year decline of 6.60%. The main business mix remains centered on non-perishables, and the outlook emphasizes controlled promotions and stable volume to protect margin while supporting modest growth. The pharmacy operation is positioned as the most actionable growth lever, with 11.41 billion US dollars in revenue last quarter and expected year-over-year change broadly aligned with the company’s forecast pace near 0.36%, aided by expanded curbside prescription pickup and service enhancements.Last Quarter Review
In the previous quarter, Albertsons Companies, Inc. reported 20.25 billion US dollars in revenue with a 27.22% gross profit margin, a GAAP net loss attributable to the parent company of 481.00 million US dollars, a net profit margin of -2.37%, and adjusted EPS of 0.48, which rose 4.35% year-over-year. A notable financial highlight was an adjusted EPS beat versus consensus, and EBIT of 429.30 million US dollars exceeded the estimate of 396.89 million US dollars; quarter-on-quarter change in net profit was -263.93%, reflecting a sharp sequential deterioration driven by items that outweighed operating strength. In the main business profile, non-perishables contributed 40.62 billion US dollars and represented 48.84% of the mix, while company-level revenue expanded 7.73% year-over-year, underscoring resilient core sales amid continued efficiency efforts.Current Quarter Outlook
Main Business: Non-Perishables
Non-perishables remain the largest revenue contributor at 40.62 billion US dollars, representing 48.84% of the mix. The central execution focus is balancing price investment with promotional cadence to sustain traffic without undermining margin. The previous quarter’s 27.22% gross profit margin indicates that merchandising, procurement, and shrink control have provided a buffer, and the company is likely to emphasize private label depth, planned promotions, and targeted price actions to support gross margin retention in a low-growth sales environment. Given consensus revenue growth of 0.36% and EPS growth of 2.70%, sustaining everyday value messaging while carefully cycling past promotional events is likely crucial; any deviation in mix, such as heavier promotional intensity or a shift toward lower-margin categories, could pressure the margin profile. Operationally, supply chain discipline—covering inventory turns, inbound freight, and distribution center productivity—matters more than usual when top-line growth is modest, helping preserve contribution from non-perishables without requiring outsized pricing actions.Most Promising Business: Pharmacy
Pharmacy posted 11.41 billion US dollars last quarter and accounted for 13.72% of the revenue mix, and it is the most promising near-term growth vector by service differentiation. The nationwide promotion of free curbside prescription pickup enriches convenience for customers with mobility constraints or tight schedules, which can lift script counts, adherence, and ancillary basket attachments. These initiatives typically support loyalty and frequency, which are helpful when broader grocery traffic normalizes. For this quarter, a pharmacy-led lift is consistent with the modest company-level growth trajectory near 0.36% year-over-year, knitting together convenience expansion with core comp stability. While gross margin details for pharmacy are not forecasted, the mix shift toward pharmacy services—when effectively merchandised alongside front-end items—can strengthen overall basket economics and offset variability elsewhere. The company’s ability to integrate pharmacy fulfillment with digital touchpoints and store operations may determine the degree of incremental contribution to EPS against the consensus of approximately 0.55.Factors Most Impacting the Stock Price This Quarter
The most consequential variables for this quarter include delivering EPS slightly above the 0.55 projection against flattish sales growth, maintaining a stable gross margin despite promotion and mix normalization, and showing clear operational progress that investors can extrapolate to the back half. First, with revenue growth near 0.36% year-over-year, margin management is central; a repeat of the previous quarter’s EPS beat would likely require disciplined cost control, measured promotional pacing, and continued progress in shrink and sourcing initiatives. Second, EBIT guidance implied by estimates—about 480.81 million US dollars with a year-over-year decline of 6.60%—highlights that investors will scrutinize SG&A trends and any non-operating items to gauge the sustainability of earnings leverage; clarity on controllable costs will be important for sentiment. Third, shareholder returns, including the recently affirmed quarterly cash dividend of 0.17 US dollars per share, contribute to the equity narrative by underscoring cash generation and capital discipline; confirmation of steady free cash flow and a consistent payout cadence provides a stabilizing signal in the face of only marginal sales growth. Any unexpected inventory rebalancing, price investment intensity, or discrete charges could move the stock, making both the gross margin commentary and EPS bridge especially important to the market’s reaction.Operational Execution and Technology Enablement
Operationally, Albertsons Companies, Inc. is signaling ongoing investment in tools that maintain product quality and strengthen process consistency. The Intelligent Quality Control initiative—an AI-enhanced inspection capability implemented at distribution centers for produce—aims to standardize quality checks for items such as strawberries and grapes and then scale across categories. By improving detection and quality consistency upstream, the company can reduce shrink, minimize rework, and help ensure customers meet expectations on freshness at the shelf. Such improvements contribute to gross margin resilience by managing waste and enhancing sell-through, and they can lower volatility in the perishable segment while freeing resources for strategic price investments. As these tools expand nationwide, their incremental effect should be cumulative rather than immediately outsized, and investors will be looking for commentary that connects quality-control gains to measurable outcomes in shrink, spoilage, and margin trend over time.Perishables and Fuel: Mix, Margin, and Traffic Interplay
Perishables contributed 26.02 billion US dollars last quarter, or 31.29% of the revenue mix, and fuel delivered 3.80 billion US dollars, or 4.57% of total. Perishables are a critical traffic driver, and their stability is often influenced by weather, seasonal promotions, and in-store execution; margin preservation tends to hinge on fresh availability, labor planning, and shrink optimization. With modest top-line growth expected this quarter, steady perishables execution combined with quality control improvements could help the company anchor grocery traffic without excessive promotion. Fuel, while smaller in mix, can be an engagement tool—fuel-related rewards and marketing tie-ins can contribute to trips and loyalty behavior; however, fuel margins are sensitive to wholesale price movements and competitive dynamics, so the quarter’s commentary around fuel profitability will help inform how much incremental contribution investors should expect in a low-growth revenue scenario.Main Business Mix and Basket Economics
The overall mix includes non-perishables at 48.84%, perishables at 31.29%, pharmacy at 13.72%, fuel at 4.57%, and other at 1.57% of revenue. The non-perishables base provides stability, particularly when promotional planning is structured around value perception rather than broad discounting. Pharmacy and perishables together can lift basket sizes when coordinated with store-level merchandising and service convenience; the added curbside prescription pickup should naturally integrate with high-frequency shopping, providing attachment opportunities to essential items. Against the consensus revenue growth of 0.36% and EPS growth of 2.70%, the company’s execution task is to protect margins while sustaining basket economics through loyalty, targeted offers, and quality assurance; investors will evaluate gross margin commentary and EPS bridge for evidence that this balance is being maintained.Analyst Opinions
Bullish opinions constitute the clear majority, with directional calls from well-known institutions outnumbering bearish views by a ratio of 100% to 0% over the past six months. Wells Fargo, through Edward Kelly, reiterated a Buy rating with an 18.00 US dollars price target, indicating confidence in operational execution and the potential for consistent cash generation to support returns. BMO Capital, via Kelly Bania, maintained a Buy rating and a 23.00 US dollars target, suggesting that incremental progress across merchandising, cost control, and service initiatives can sustain earnings quality even when headline revenue growth is near flat year-over-year. Telsey Advisory Group’s Joe Feldman reaffirmed a Buy and a 22.00 US dollars target, framing the stock within a stability narrative where modest comp growth, constrained promotional risk, and cost discipline can keep EPS near or above expectations.The majority view emphasizes that modest sales growth is acceptable provided margin integrity and EPS reliability are evident. Analysts are effectively calibrating to a quarter where the top-line is not the primary driver; instead, they see near-term shareholder return continuity and shrink reduction as catalysts that can improve sentiment. Under this lens, the expanded curbside prescription pickup is expected to bolster traffic and script counts, which, coupled with produce quality control gains, can reduce margin leakage and contribute small but meaningful EPS support. The bullish perspective further expects that the company’s operational improvements are transferable across categories, implying that AI-enhanced quality control—once scaled—should be reflected in improved waste metrics and more stable perishable margins. Although segment-level gross margin forecasts are not provided, the bullish case is essentially that the company’s practical store and supply chain actions can deliver a more consistent earnings profile than the headline revenue trajectory suggests.
Importantly, the bullish stance does not rely on aggressive top-line assumptions; it is grounded in the view that the company’s margin discipline and service differentiation can hold the line in a quarter where revenue is guided to rise 0.36% year-over-year and EPS to 0.55 with a 2.70% year-over-year increase. At the same time, analysts expect investors to focus on the EBIT print near 480.81 million US dollars and the qualitative commentary on costs and non-operating items to validate EPS trajectory. If management articulates a clear pathway from operational gains—shrink, procurement, and store execution—to ongoing margin stability, the bullish scenario suggests room for estimate revision or at least stronger confidence in the back-half outlook. Overall, the majority opinion is that Albertsons Companies, Inc. can meet or slightly exceed EPS expectations even if the revenue line shows only fractional year-over-year growth, and that consistent execution around pharmacy convenience and produce quality standards can add incremental reliability to the earnings stream in the current quarter.
Comments